Biosante Pharmaceuticals (BPAX)
Biosante Pharmaceuticals Revenue Growth: 100.0%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BPAX Revenue Growth Rankings
| Overall | 96th percentile | 141 of 4358 |
| Sector | 90th percentile | 44 of 456 in Healthcare |
| Industry | 75th percentile | 31 of 126 in Biotechnology |
BPAX Revenue Growth Range, Past 5 Years
| Minimum | -97.66% | Dec 2007 |
| Maximum | 3233% | Mar 2010 |
| Average | 266.0% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BPAX related companies
BPAX News
Anyone have insight on $bpax ? Is this another game the shorts are playing?
about 6 days ago by stock_sniper
about 6 days ago by stock_sniper
RT @HulkHogan Looks like it could be another monster volume day on $BPAX/over 4M traded in 1st half hour!
about 6 days ago by mainetrader
about 6 days ago by mainetrader
@randal $BPAX When are people going to learn that past performance does not predict future performance. You can't predict price by a chart
about 6 days ago by Flynt2012
about 6 days ago by Flynt2012
RT @MarkeScope: Top Winners last Monday, May 21, 2012
#NASDAQ :
$ZNWAZ,$BPAX,$BWOWW,$ROSG,$VIMC
#StockMarket #MarkeScope #invest #money
about 6 days ago by Bw1128
about 6 days ago by Bw1128
@adamfeuerstein $GALE do you think this piggy going back down below 1.20 today or is $BPAX a better short?
about 6 days ago by randal
about 6 days ago by randal
@BioDueDiligence and if $BPAX pops again tomorrow sir?? will it just be a miracle??? LOL
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
RT @ankitm514: $BPAX--56%+ today. WTF. Told you to hold. 1 have 500k shares.
about 6 days ago by HulkHogan
about 6 days ago by HulkHogan
$BPAX up 56% on no news?? The only thing I can think of is insider buying!!!!
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
$BPAX up 52%, vow longs deserve this runup as paid bashers have really created artificial negative sentiment here #WELLKNOWN BASHERS $$
about 6 days ago by peterumble
about 6 days ago by peterumble
$ROSG again effect of Obtaining Medicare Coverage of miRview mets2 Assay (Wed, May 16) thats big for tiny mkt cap co. $ARNA $BPAX
about 6 days ago by EPS_MomentuM
about 6 days ago by EPS_MomentuM
@mainetrader $BPAX wouldn't they have to reverse split to stay listed on the nasdaq???
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
$bpax hopefully most of the shorts are out. But if they get in again, watch out.
about 6 days ago by stock_sniper
about 6 days ago by stock_sniper
$BPAX still not getting involved before reverse split. Ya there is volume but the stock is under 50 cents. Looks like it is coming back down
about 6 days ago by jimmieB
about 6 days ago by jimmieB
Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Biosante Pharmaceuticals, Inc. for Securities Fraud
May 09, 12:24PM Business Wire
May 09, 12:24PM Business Wire
Small Biotech Companies Look to Benefit From Shift to "First to File" Patent System
May 03, 8:20AM Marketwire
May 03, 8:20AM Marketwire
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
BioSante Pharmaceuticals, Inc. to Present at BioCentury Future Leaders in the Biotech Industry Conference
Apr 17, 7:55AM Business Wire
Apr 17, 7:55AM Business Wire
BioSante (BPAX) Reports Encouraging Data from Recent Pill-Plus Studies
Mar 20, 7:56AM Street Insider
Mar 20, 7:56AM Street Insider
BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation
Mar 20, 7:55AM Business Wire
Mar 20, 7:55AM Business Wire
FAST Act to Modernize Approval Process -- Cardium and BioSante Poised to Benefit
Mar 19, 8:20AM Marketwire
Mar 19, 8:20AM Marketwire
BioSante Pharmaceuticals Reports Financial Results for 2011 and Corporate Highlights
Mar 13, 5:04PM Business Wire
Mar 13, 5:04PM Business Wire
BioSante Pharmaceuticals, Inc. to Present at Roth Health Care Conference
Mar 09, 7:55AM Business Wire
Mar 09, 7:55AM Business Wire
BioSante Pharma (BPAX) Reports Encouraging Data from GVAX in mCRPC Phase I w/ Escalated Dosage
Mar 05, 7:57AM Street Insider
Mar 05, 7:57AM Street Insider
BioSante’s Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study
Mar 05, 7:55AM Business Wire
Mar 05, 7:55AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BPAX | 0.5183 | -0.00 | -0.25% | 62.63M |
| BP | 38.36 | +0.13 | +0.34% | 121.32B |
| BOXC | 25.90 | +0.49 | +1.93% | |
| BOX | 18.08 | -0.22 | -1.20% | 366.84M |
| BOSC | 0.7601 | -0.00 | -0.51% | 3.398M |
| BKBK | 8.12 | +0.00 | +0.00% | 17.38M |
| BK | 20.64 | -0.09 | -0.43% | 24.87B |
| BJZ | 16.68 | +0.00 | +0.01% | |
| BJRI | 44.56 | -0.13 | -0.29% | 1.244B |
| BJK | 31.62 | +0.06 | +0.19% |